The board of directors of the Pittsburgh Life Sciences Greenhouse has approved the nomination of Lansing Taylor as chairman. He takes over for co-chairs Mark Nordenberg and Jared Cohon.
Taylor is already on the board of PLSG and recently served as chairman and CEO of high-content cell screening firm Cellomics, which he founded and was acquired by Thermo Fisher Scientific in September 2005. He also was a co-founder, member of the board, and scientific advisor to Biological Detection Systems, which was sold to Amersham Biosciences in 1996.
BioReliance has tapped David Dodd to be president, CEO, and chairman of the company’s board of directors.
Dodd formerly was president and CEO of Serologicals and prior to that he was president and CEO of Solvay Pharmaceuticals. Dodd also formerly was employed at Abbott Laboratories, Bristol-Myers Squibb, and McDonnell-Douglas Healthcare Systems.